Atopic dermatitis, also known as eczema, is a chronic, inflammatory skin condition characterized by intense itching, dry skin, and recurrent flare-ups of red, inflamed lesions. It is driven by a ...

A team of leading clinical research scientists from the Departments of Psychiatry and Dermatology at the Icahn School of ...

A new study published in the Journal of the American Medical Association showed that in the treatment of atopic dermatitis (AD), once-daily oral ICP-332, a tyrosine kinase 2 inhibitor, ...

A meta-analysis finds probiotics may improve patient-reported quality-of-life scores in children and adolescents with AD in the short term, but data do not show clinical improvements.

Findings provide rationale for targeted strategy in psychiatry that may lead to new personalized treatments for major depressive disorder and other conditions ...

The Phase IIa trial of EVO301 showed similar EASI reduction to Sanofi’s flagship AD drug Dupixent.

Rocatinlimab’s novel approach as an investigational T-cell rebalancing therapy directly targeting the OX40 receptor expressed on pathogenic T-cells shows potential to deliver long-term disease control ...

A staged approach for a patient decision aid can help to deliver complex information and facilitate shared decision-making in adults with atopic dermatitis.

Atopic dermatitis (AD) is a chronic disease that affects an increasing number of children and adults. The skin is dry and irritated, and the itching can be so severe that it interferes with sleep and ...

Please provide your email address to receive an email when new articles are posted on . “Clinician awareness of atopic comorbidities and the additional impact that these conditions have on patients ...

Johnson & Johnson has discontinued a phase 2 trial of one of its pipeline candidates for atopic dermatitis (AD), after it failed to meet efficacy expectations. In a statement, J&J said that ...